Healthcare
Women in PE: Foresight’s Alvarez on SME deployment plans, regional expansion drive
Partner Claire Alvarez speaks to Unquote about opportunities in the current market and the UK-based sponsor’s diversity ambitions
Forbion raises combined EUR 1.35bn for venture and growth funds
Ventures Fund VI closes on EUR 750m and Growth Opportunities II on EUR 600m with both upsized by over 60%
Gilde Healthcare hits EUR 600m target for Venture&Growth VI
Fund is 50% larger than predecessor thanks to “loyal” LP base; seeks late-stage deployment in medtech, digital health and therapeutics
The Bolt-Ons Digest – 17 April 2023
Unquote’s selection of the latest add-ons with Triton's BFC Group, Seven2's Groupe Crystal, Palatine's FourNet and more
Wellspect bidders CVC, KKR, PAI, EQT expected to progress into second round
US trade owner attempted a previous sale for the Swedish bladder and bowel-control products specialist in 2018
Spending bottom dollar: Valuation gaps take Q1 buyout levels back to 2009
Sponsors make just 95 buyouts in Europe in the first quarter - a figure not seen since Sony sold 12m floppy discs in one year
PE roll-up strategies face regulatory heat with focus on consumer industries
With longer holding periods facilitating more bolt-ons, regulators including the UK's CMA are intervening
GP Profile: Metric Capital confident of structured capital strategy demand with multiple exits in pipeline
UK-based sponsor banks on appeal of its strategy as an alternative to private equity and debt providers
KKR holds USD 8bn European Fund VI buyout fund close with 12.5%-plus GP commitment
European Fund VI will deploy equity tickets of EUR 250m-750m in six core sectors
ECI reaps 2.7x return on 4ways sale to EQT-backed Evidia
Sale process for UK-based teleradiology platform had been running since September 2022
VC Profile: Target Global assesses B2B opportunities in final stretch of current fund deployment
Nearing full deployment for its second growth fund, pan-European VC firm outlines plans to back defensive B2B models and institutionalise its co-investment strategy and LP base
Large-cap sponsors circle Qiagen bioinformatics arm ahead of indicative bids
Potential PE bidders are assessing performance and market share of the Netherlands-headquartered business
Riverside acquires Dastex and Vita Verita
Sponsor plans to pursue a buy-and-build strategy for new European clean room contamination control group
EQT closes LSP Dementia on EUR 260m hard cap
Series A-focused fund exceeded its EUR 100m target and extended fundraising after increased LP interest in its strategy
Newton Biocapital heads for year-end close for second, EUR 150m life sciences fund
Belgian-Japanese VC has raised EUR 50m to date and is lining up exits from its debut fund
Sofinnova launches digital medicine strategy
Life sciences sponsor’s sixth strategy will deploy EUR 2m-EUR 8m tickets in seed and Series A
Cinven’s indicative EUR 10 per share Synlab bid seen as below fair value
Sponsor listed the laboratory testing service provider at EUR 18 per share in 2020
Synova’s Clyde Munro exit parked in waiting room
Dental clinic sale could resume with improved macro conditions and after post-acquisition trasing plays out
GP Profile: BGF to deploy GBP 500m-plus per year for minority growth deals with entrepreneurs
UK and Ireland-based growth investor remains committed to filling a market gap for founders who want flexibility and control
European sponsors sidestep panic, concede gloom over bank woes
Fallout from Credit Suisse collapse adds to slew of macroeconomic challenges for PE dealmaking and fundraising
Keyhaven eyes Q4 2023 fund launch amidst lower mid-market GP-leds boom
Secondaries firm looks ahead to fourth fund; sweet spot of EUR 50m-100m for deals but can go up to EUR 500m
Nordic picks Jefferies for upcoming Sunrise Medical auction
German wheelchair specialist was acquired in 2015 and moved to a continuation fund in 2018
AnaCap exits Oona Health in EUR 302m sale to Topdanmark
Deal for Danish health insurance provider generates a 4x money multiple and 40% IRR
Afinum nears EUR 410m-EUR 420m fund close; mulls new fundraise
Plans for Fund 10 to be contemplated by mid-2024 “at the earliest” as GP advances on succession changes